15:06 EDT Romness sees potential FDA approval, PVR as key to OS Therapies (OSTX) stock
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSTX:
- OS Therapies Raises $4.2M Through Warrant Exercise
- OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating
- OS Therapies granted End of Phase 2 Meeting by FDA to review OST-HER2 program
- Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress
- OS Therapies reports ‘positive’ results from Phase 2b trial of OST-HER2